Donation

Resource
In the News: Myeloma Debates, Drug Costs, Reading that MattersIn his blog this week, IMF Chairman Dr. Brian Durie recaps the…
October 08, 2015
Resource
In the News: Myeloma Debates, Drug Costs, Reading that MattersIn his blog this week, IMF Chairman Dr. Brian Durie recaps the…
October 08, 2015
Resource
Black Swan Research Initiative Team Member Wins Prestigious AwardDr. Bruno Paiva, a member of IMF's Black Swan Research…
October 01, 2015
Resource
IMF Receives Highest 4-Star Charity Rating for 11 Years RunningThe IMF has been awarded Charity Navigator’s 4-star, highest…
September 03, 2015
Resource
Can a "Longevity Feast" Be the Key to Longer Life?In his blog this week, IMF Chairman Dr. Brian Durie discusses a recent…
August 06, 2015
Resource
   …
July 09, 2015
Resource
   …
July 02, 2015
Resource
New Study Investigates Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and/or Refractory MyelomaThe results of the…
September 24, 2015
Resource
Huge Interest in Toxic Chemicals Triggered by Last Week's Blog: Follow-up NotesIn a follow-up to last week's blog about Agent…
September 17, 2015
Resource
More Evidence Links Toxic Chemical Exposure to MGUS and MyelomaFor the first time, direct serum measurements of the known…
September 10, 2015
Resource
Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in StudyA study published in the…
August 27, 2015
Resource
Is Precision Medicine What We Need?In his blog this week, IMF Chariman Dr. Brian Durie compares two opinions on the value of…
August 20, 2015
Resource
Proposed "Value Framework" Could Limit Patient Access to Myeloma DrugsThe American Society of Clinical Oncology (ASCO) has…
August 13, 2015
Resource
Is There a Link Between a Genetic Variation and Poor Myeloma Survival Rate?In his blog this week, IMF Chairman Dr. Brian…
July 30, 2015
Resource
IMF's Black Swan Research Initiative Makes Inroads on Pathway to a CureThe Black Swan Research Initiative® is moving…
July 23, 2015
Resource
Is There a Tie Between Leisure Time Spent Sitting and Cancer Risks?In his blog this week, IMF Chairman Dr. Brian Durie…
July 16, 2015
Resource
Dear ReaderA message from IMF President Susie Novis…
November 17, 2015
Resource
Dear ReaderA message from IMF President Susie NovisSpecial…
July 29, 2015
Resource
Dear ReaderA message from IMF President Susie NovisScientific & ClinicalMyeloma Treament Progress Accelerates in US and EuropeIMF Chairs Tokyo Flow WorkshopNurse Leadership Board…
April 02, 2015
Resource
Myeloma MinuteDecember 3, 2015Live from Orlando, FL: Latest News from the 2015 Annual Meeting of the American Society of Hematology!The IMF team brings you all the latest news from the 2015 Annual Meeting of the…
December 03, 2015
Resource
Best Myeloma Research from American Society of Hematology (ASH) 2015 Annual MeetingIn his blog this week, IMF Chairman…
November 19, 2015
Blog post
The 2015 annual meeting of the American Society of Clinical Oncology (ASCO) is almost upon us. It is being held in Chicago from May 29thto June 2nd. This year, approximately 100 abstracts will focus on myeloma. Thus, although many fewer than at the annual meetings of…
May 21, 2015
Blog post
Feedback from the large International Myeloma Workshop (IMW) meeting in Rome is still filtering in. There were around 3,000 attendees for this mini-ASH type symposium focused on myeloma. The event offers a comprehensive update for those not immersed in myeloma through their research or daily…
October 08, 2015
Videos
Introduction: Elotuzumab is an immunostimulatory monoclonal antibody (mAb) that recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein highly expressed by myeloma and natural killer cells. Elotuzumab has a dual mechanism of action, directly activating…
December 07, 2015
Audio
Chinese Master Class 2015
August 09, 2016
Videos
Case Study #1: MGUS, SMM, Clinical Trials, New MM Diagnostic Criteria, Newly Diagnosed MM, Minimal Residual DiseaseJoseph D. Tariman, PhD, ANP-BCBeth Faiman, PhD , MSN, APRN-BC, AOCN®…
October 12, 2015
Videos
Case Studies #2: Relapsed Myeloma, Clonal Evolution, Treatment for Relapsed Myeloma, Drugs in DevelopmentSandra Kurtin, RN, MS, AOCN®, ANP-CBeth Faiman, PhD , MSN, APRN-BC, AOCN® …
October 12, 2015
Videos
click on the image above to watch the teleconference(to view the teleconference in fullscreen, click on the bottom right square icon beside the YouTube logo)Learn more about…
October 13, 2015
Videos
Case Studies #1 (Cont.): Newly Diagnosed MM Treatment, Adherence, Transplantation, Clinical TrialsTeresa Miceli, RN, BSN, OCN®Beth Faiman, PhD , MSN, APRN-BC, AOCN® …
October 01, 2015
Videos
IMWG Myeloma Experts debate the latest trends in treatmentJune 10, 2015Vienna AustriaSince 2001, the International Myeloma Working Group’s achievements have changed the landscape of myeloma research. This collaborative effort has brought about breakthroughs in treatment…
June 10, 2015
Videos
Dr. Paul RichardsonDana-Farber Cancer InstituteBoston, Massachusetts, USAABOUT PAUL RICHARDSON, MDPaul Richardson, M.D. is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute…
October 13, 2015
Videos
Dr. Ken AndersonDana-Farber Cancer InstituteBoston, Massachusetts, USAABOUT KENNETH C. ANDERSON, MDDr. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and…
October 13, 2015
Videos
Dr. Shaji Kumar overview on what abstracts and posters generated the most excitement for the field of Multiple Myeloma at ASCO 2015.ABOUT SHAJI K. KUMAR, MDDr. Shaji Kumar is the Medical Director for the Cancer Center Clinical Research Office at the Mayo Clinic…
October 13, 2015
Videos
Dr. Saad UsmaniLevine Cancer InstituteCarolinas Healthcare SystemCharlotte, NCWith support from Amgen, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, and Takeda Oncology.ABOUT SAAD USMANI, MDDr. Saad Usmani is Chief of Plasma Cell…
December 07, 2015
Videos
Dr. Sagar LonialEmory UniversityAtlanta, GAWith support from Amgen, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, and Takeda Oncology.ABOUT SAGAR LONIAL, MD, FACPDr. Sagar Lonial is Chief Medical Officer at the Winship Cancer Institute…
December 07, 2015
Videos
Dr. Morie GertzMayo ClinicRochester, MNWith support from Amgen, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, and Takeda Oncology.ABOUT MORIE GERTZ, MDDr. Morie Gertz is a Hematologist/Oncologist and Chair of General Internal Medicine…
December 07, 2015
Videos
Dr. Kenneth AndersonDana-Farber Cancer InstituteBoston, MAWith support from Amgen, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, and Takeda Oncology.ABOUT KENNETH C. ANDERSON, MDDr. Anderson graduated from Johns Hopkins Medical School,…
December 07, 2015
Videos
In this video, Dr. Paul Richardson of the Dana-Farber Cancer Insitute talks about what he thinks is the most exciting data shared at this year's American Society of Hematology (ASH) annual conference, and that is, the data related to the use of immuno-onco (I-O) drugs in treating multiple…
January 08, 2016
Videos
IMWG Conference SeriesASH 2015Orlando, FLDr. Brian DurieDr. Joseph MikhailDr. Antonio PalumboDr. Paul Richardson
January 08, 2016
Videos
 Join us for a provocative program format that includes “point and counterpoint” presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma.Interact with…
October 20, 2015
Videos
click on the image above to watch the teleconference(to view the teleconference in fullscreen, click on the bottom right square icon beside the YouTube logo)Join Dr. Brian G.M…
January 11, 2016
Videos
IMWG Conference SeriesASH 2015Orlando, FL, USA
January 08, 2016
Videos
High dose chemotherapy plus autologous transplantation (ASCT) is considered a standard of care for newly diagnosed myeloma patients younger than 65 years of age. The high complete response rate (CR) achieved with the triplet combination of immunomodulatory drugs + proteasome inhibitors +…
January 08, 2016
Videos
The IMF brings you highlights from the 50th annual meeting of the American Society of Clinical Oncology (ASCO) held May 29-June 2, 2015 in Chicago, Illinois. The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties. …
October 13, 2015
Videos
IMWG Conference SeriesASH 2015Orlando, FLDr. Brian G.M. DurieDr. Joseph MikhailDr. Antonio PalumboDr. Paul Richardson
January 08, 2016
Videos
Introduction: Daratumumab (DARA) is a novel human CD-38-targeting monoclonal antibody in clinical development for multiple myeloma (MM).  In two clinical studies (NCT00574288 [GEN501] and NCT01985126 [Sirius]), DARA monotherapy showed remarkable clinical activity and…
December 07, 2015
Videos
Dr. Meletios DimopoulosNational and KapodistrianUniversity of AthensAthens, GreeceBackground: ENDEAVOR (NCT01568866) is comparing Kyprolis and dexamethasone with Velcade and dexamethasone with patients with relapsed multiple myeloma. The…
October 13, 2015
Videos
IMWG Conference SeriesIMF Chairman of the Board Dr. Brian G.M. Durie leads a discussion on how to asses new agents in the treatment of multiple myeloma based on research from the American Society of Hematology (ASH) annual conference in 2015 in Orlando, Florida.
January 08, 2016
Videos
Dr. Sagar LonialEmory UniversityAtlanta, GA, USABackground: DARA, a human anti-CD38 IgG1κ mAb, has single agent activity and is well-tolerated in rel/ref MM (Lokhorst HM et al. ASCO 2014). This ongoing phase 2 study (NCT01985126) evaluated DARA…
October 13, 2015

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.